This Week in Psychedelics

Could psychedelics reduce psychotic symptoms in teens? Plus Cybin, Inc. gets closer to first FDA approved psychedelic therapeutic for MDD.

March 15, 2024

This Week...

Cybin, Inc. announced that it received breakthrough therapy designation from the FDA for its psilocybin analog, CYB003. If approved, this will be the first known adjunctive psychedelic-based therapeutic for the treatment of major depression disorder (MDD).

The company also announced that its Phase 2 trial of CYB003 in MDD demonstrated “robust and sustained improvement” in depression symptoms at four months with 75% of participants receiving two 16 mg doses achieving remission and no longer showing signs of depression.

Here’s more:

Utah lawmakers unanimously approved a bill to authorize a pilot program for hospitals to administer psilocybin and MDMA as an alternative treatment option. It now goes to the governor who signed into law a bill that created a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use. Check it out:

The American Medical Association (AMA) published a new report that found psychedelic use was linked to lower rates of psychotic symptoms in adolescents.

The findings in this study suggest that, after adjusting for other drug use, naturalistic use of psychedelics may be associated with lower rates of psychotic symptoms among adolescents. At the same time, the association between psychedelic use and manic symptoms seems to be associated with genetic vulnerability to schizophrenia or bipolar I disorder. Here’s more:

Did You Know?

Did you know that the first time endocrinologist and best-selling author Deepak Chopra took LSD, he said he felt his consciousness shift while staring at a picture of Mother Teresa? He also said the experience left him with a feeling of overwhelming compassion and a desire to alleviate suffering.

Such experiences are not uncommon with LSD, but with his international influence, Chopra was able to turn this experience into a calling to educate the masses on the benefits of psychedelics. Today, Chopra is considered one of the most effective and successful advocates for the medicinal use of psychedelics due to his massive following, which includes 3.7 million Facebook followers, 3 million Twitter followers, and 2.9 million Instagram followers.